CRBP is a high risk play on its fast track synthetic cannabinoid chronic inflammation treatment.
The lead indication has orphan status for systemic sclerosis (~ 90,00 patients)
12-month data for this indication will be read out 5/18. Full Ph3 data is not expected until 2020.
The compound is also in Ph2 in: 1) dermatomyositis 2) cystic fibrosis.
Cash will provide a runway into 2019. CRBP will likely take advantage of any positive data to raise capital.
The cannabinoids have been shown repeatedly to work as part of the entourage effect. I believe single a synthetic cannabinoid will always be worth less than a natural spectrum of cannabinoids.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.